BioSpace News Archive

Cogent Biosciences, Inc. (“Cogent”) (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 11,794,872 shares of its common stock at a public offering price of $9.75 per share.

Penumbra, Inc. (NYSE: PEN) today announced that its chief executive officer is scheduled to participate in a discussion with Bank of America on Tuesday, December 8, 2020.

Ensemble Orthopedics Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its Ensemble CMC Implant.

Solidarity HealthShare (SHS), a non-profit, affordable, ethical healthcare sharing ministry alternative to traditional health insurance has partnered with Cancer Treatment Centers of America® (CTCA) to provide its members access to world-class affordable cancer care.

Prothena Corporation plc announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 90,000 ordinary shares of the Company.

Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the resignation of Ernst & Young Hua Ming LLP (“EY”), which previously was the independent registered public accounting firm of Anpac Bio, on November 3, 2020 and the appointment of Friedman LLP (“Friedman”) as the Company’s independ

HealthEquity, Inc., the largest independent health savings account custodian and leader in consumer directed benefits, announced that Stuart Parker has been elected to the Company’s Board of Directors effective immediately and appointed to serve on the Compensation Committee and Cybersecurity Subcommittee of the Audit and Risk Committee.

Blueprint Medicines Corporation announced that, effective on December 1, 2020, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 16,354 shares of its common stock and an aggregate of 8,174 restricted stock units to eight new employees under Blueprint Medicines’ 2020 Inducement Plan.

Flexion Therapeutics, Inc. announced equity inducement grants to six new employees consisting of 22,798 restricted stock units.

Imagine swabbing your nostrils, putting the swab in a device, and getting a read-out on your phone in 15 to 30 minutes that tells you if you are infected with the COVID-19 virus